Anavex Advances Drug Candidates for Treatment of Epilepsy

Results in epilepsy animal models demonstrate that ANAVEX 2-73 and its active metabolite ANAVEX 19-144 have potent anticonvulsant, anti-amnesic and neuroprotective properties Geneva, Switzerland — December 6, 2007 — Anavex Life Sciences Corp. (“ANAVEX”) (OTCBB: AVXL) today announced promising developments with ANAVEX 2-73 and ANAVEX 19-144, the company’s lead drug candidates to treat epilepsy. During…